2018\u5e745\u67089\u65e5<\/p>\n
³Ô¹Ï±¬ÁÏ Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
<\/p>\n
³Ô¹Ï±¬ÁÏ Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b ³Ô¹Ï±¬ÁÏ)\u306f\u3001\u30b9\u30a4\u30b9\u306b\u62e0\u70b9\u3092\u7f6e\u304f\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f01\u696d\u3067\u3042\u308bDebiopharm Group™\u306e\u30b0\u30eb\u30fc\u30d7\u4f01\u696d\u3001Debiopharm International SA<\/a><\/strong>\uff08\u4ee5\u4e0bDebiopharm\u793e\uff09\u304c\u3001³Ô¹Ï±¬ÁÏ Vault eTMF<\/a><\/strong>\u3092\u63a1\u7528\u3057\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002³Ô¹Ï±¬ÁÏ Vault eTMF\u3092\u5229\u7528\u3057\u3001\u5358\u4e00\u306e\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u4e0a\u3067\u500b\u3005\u306e\u533b\u85ac\u54c1\u958b\u767a\u6a5f\u95a2\uff08CRO\uff09\u3068\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u3059\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u6cbb\u9a13\u30de\u30b9\u30bf\u30fc\u30d5\u30a1\u30a4\u30eb\uff08TMF\uff09\u30d7\u30ed\u30bb\u30b9\u5168\u4f53\u306e\u30aa\u30fc\u30d0\u30fc\u30b5\u30a4\u30c8\u3092\u6539\u5584\u3057\u3001\u3088\u308a\u7dca\u5bc6\u306a\u5354\u696d\u3092\u9032\u3081\u307e\u3059\u3002 (\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001³Ô¹Ï±¬ÁÏ\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059)<\/p>\n <\/p>\n Debiopharm\u793e\u306e\u30af\u30ea\u30cb\u30ab\u30eb\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u62c5\u5f53\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u3067\u3042\u308bChristian A. Aeschlimann\u6c0f\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c³Ô¹Ï±¬ÁÏ\u306f\u3001\u5f53\u793e\u306e\u81e8\u5e8a\u8a66\u9a13\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u306e\u5408\u7406\u5316\u3092\u652f\u63f4\u3057\u3066\u3044\u307e\u3059\u3002³Ô¹Ï±¬ÁÏ Vault eTMF\u306b\u3088\u308a\u3001\u79c1\u305f\u3061\u306f\u5e38\u306b\u6b63\u78ba\u3067\u6700\u65b0\u306eTMF\u3092\u7dad\u6301\u3067\u304d\u3001\u540c\u4e00\u306e\u30b7\u30b9\u30c6\u30e0\u3067\u4f5c\u696d\u3059\u308b\u3053\u3068\u3067\u3001\u5916\u90e8\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u3068\u306e\u8abf\u6574\u304c\u5bb9\u6613\u306b\u306a\u308a\u307e\u3059\u3002\u300d<\/p>\n Debiopharm\u793e\u306f\u3001\u6cbb\u9a13\u4f9d\u983c\u8005\u3068\u3057\u3066\u3001ICH E6(R2) \u306b\u6e96\u62e0\u3057\u3066\u81e8\u5e8a\u8a66\u9a13\u5168\u4f53\u3092\u901a\u3058\u305f\u30aa\u30fc\u30d0\u30fc\u30b5\u30a4\u30c8\u3092\u7dad\u6301\u3059\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002\u5916\u90e8\u30d1\u30fc\u30c8\u30ca\u30fc\u306f\u3001\u540c\u793e\u304c\u304b\u3064\u3066\u5229\u7528\u3057\u3066\u3044\u305f\u30aa\u30f3\u30d7\u30ec\u30df\u30b9\u306eeTMF\u306b\u306f\u30a2\u30af\u30bb\u30b9\u3067\u304d\u306a\u304b\u3063\u305f\u305f\u3081\u3001CRO\u306f\u72ec\u81ea\u306e\u30b7\u30b9\u30c6\u30e0\u3092\u5229\u7528\u3057\u3066\u6587\u66f8\u3092\u5b9a\u671f\u7684\u306b\u79fb\u7ba1\u3055\u305b\u3066\u3044\u307e\u3057\u305f\u3002\u3064\u307e\u308a\u3001Debiopharm\u793e\u306f\u3001CRO\u306eTMF\u696d\u52d9\u306b\u5bfe\u3057\u3001\u30ea\u30a2\u30eb\u30bf\u30a4\u30e0\u306e\u5b8c\u5168\u306a\u53ef\u8996\u6027\u3092\u78ba\u4fdd\u3067\u304d\u3066\u3044\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n ³Ô¹Ï±¬ÁÏ Vault eTMF\u306f\u3001\u8a66\u9a13\u306e\u30c9\u30ad\u30e5\u30e1\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306b\u304a\u3051\u308b\u60c5\u5831\u306e\u4e00\u5143\u7ba1\u7406\u3092\u5b9f\u73fe\u3057\u307e\u3059\u3002\u6cbb\u9a13\u4f9d\u983c\u8005\u3068CRO\u306f\u3001\u8a66\u9a13\u5b9f\u65bd\u306e\u90fd\u5ea6\u3001TMF\u6587\u66f8\u3068\u30d7\u30ed\u30bb\u30b9\u3092\u540c\u4e00\u30b7\u30b9\u30c6\u30e0\u4e0a\u3067\u30ea\u30a2\u30eb\u30bf\u30a4\u30e0\u306b\u7ba1\u7406\u3067\u304d\u307e\u3059\u3002\u3053\u308c\u306b\u3088\u308aDebiopharm\u793e\u306f\u3001\u5e38\u306b\u67fb\u5bdf\u306e\u6e96\u5099\u304c\u6574\u3063\u305f\u72b6\u614b\u3067TMF\u3092\u7dad\u6301\u3067\u304d\u308b\u305f\u3081\u3001\u30d1\u30fc\u30c8\u30ca\u30fc\u306e\u6a19\u6e96\u696d\u52d9\u624b\u9806\u66f8\uff08SOP\uff09\u901a\u308a\u306e\u696d\u52d9\u9042\u884c\u3092\u9075\u5b88\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3057\u305f\u3002<\/p>\n Debiopharm\u793e\u306e\u30af\u30ea\u30cb\u30ab\u30eb\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u30de\u30cd\u30b8\u30e3\u30fc\u3067\u3042\u308bVincent Demeautis\u6c0f\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c\u5f53\u793e\u306f\u7d99\u7d9a\u7684\u306a\u6539\u5584\u3092\u8ffd\u6c42\u3059\u308b\u4e2d\u3067\u3001\u4f5c\u696d\u3092\u3088\u308a\u52b9\u7387\u7684\u306b\u884c\u3044\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3051\u308b\u54c1\u8cea\u306e\u30c9\u30ad\u30e5\u30e1\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u3092\u7dad\u6301\u3067\u304d\u308b\u3088\u3046\u306b\u3059\u308b\u305f\u3081\u3001³Ô¹Ï±¬ÁÏ Vault eTMF\u3092\u63a1\u7528\u3057\u307e\u3057\u305f\u3002\u3053\u306e\u5358\u4e00\u306e\u30b7\u30b9\u30c6\u30e0\u3092TMF\u306e\u3059\u3079\u3066\u306e\u30d7\u30ed\u30bb\u30b9\u3092\u9032\u3081\u308b\u5404CRO\u3068\u5171\u6709\u3059\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u8907\u6570\u306eTMF\u30bd\u30fc\u30b9\u3092\u7ba1\u7406\u3057\u3001\u4e00\u81f4\u3055\u305b\u308b\u5fc5\u8981\u304c\u306a\u304f\u306a\u308b\u3068\u540c\u6642\u306b\u3001\u3088\u308a\u8fc5\u901f\u306a\u5bfe\u5fdc\u304c\u3067\u304d\u308b\u3046\u3048\u3001\u793e\u5185\u5916\u306e\u8a66\u9a13\u30c1\u30fc\u30e0\u30e1\u30f3\u30d0\u30fc\u3068\u306e\u3088\u308a\u7dca\u5bc6\u306a\u9023\u643a\u304c\u53ef\u80fd\u306b\u306a\u308a\u307e\u3059\u3002\u300d<\/p>\n \u66f4\u306bDebiopharm\u793e\u306f\u3001³Ô¹Ï±¬ÁÏ Vault eTMF\u306e\u30ec\u30dd\u30fc\u30c8\u3068\u30c0\u30c3\u30b7\u30e5\u30dc\u30fc\u30c9\u6a5f\u80fd\u306b\u3088\u308a\u3001TMF\u306e\u5b8c\u4e86\u7387\u3001\u9069\u6642\u6027\u3001\u6b63\u78ba\u6027\u3092\u78ba\u8a8d\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3059\u3002\u3053\u308c\u306b\u3088\u308a\u540c\u793e\u306f\u3001\u30c9\u30ad\u30e5\u30e1\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u72b6\u614b\u3068\u54c1\u8cea\u3092\u78ba\u8a8d\u3057\u3001\u3069\u306e\u3088\u3046\u306a\u554f\u984c\u304c\u767a\u751f\u3057\u3066\u3082\u30d7\u30ed\u30a2\u30af\u30c6\u30a3\u30d6\u306b\u89e3\u6c7a\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3059\u3002<\/p>\n Debiopharm\u793e\u3067³Ô¹Ï±¬ÁÏ Vault eTMF\u306e\u5c0e\u5165\u3092\u63a8\u9032\u3057\u305f\u30b7\u30cb\u30a2\u30af\u30ea\u30cb\u30ab\u30eb\u30c8\u30e9\u30a4\u30a2\u30eb\u30a2\u30bd\u30b7\u30a8\u30fc\u30c8\u3001Sofie Lemmens\u6c0f\u306f\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c³Ô¹Ï±¬ÁÏ Vault eTMF\u306f\u3001\u5f53\u793e\u306e\u73fe\u5728\u305d\u3057\u3066\u5c06\u6765\u306e\u30cb\u30fc\u30ba\u306b\u5408\u81f4\u3057\u305f\u3001\u5e02\u5834\u3067\u6700\u3082\u512a\u308c\u305f\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3067\u3057\u305f\u3002\u3053\u306e\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306f\u3001TMF\u306e\u54c1\u8cea\u3068\u30a2\u30af\u30bb\u30b9\u3092\u6539\u5584\u3059\u308b\u305f\u3081\u306e\u3001\u793e\u5185\u306e\u30c1\u30fc\u30e0\u3059\u3079\u3066\u306b\u5bfe\u3059\u308b\u91cd\u8981\u306a\u6295\u8cc7\u3067\u3057\u305f\u3002\u300d<\/p>\n ³Ô¹Ï±¬ÁÏ Vault eTMF\u306e\u5c0e\u5165\u306b\u3088\u308a\u3001Debiopharm\u793e\u306f\u7d71\u5408\u5316\u3055\u308c\u305f\u81e8\u5e8a\u8a66\u9a13\u30e2\u30c7\u30eb\u3078\u306e\u7b2c\u4e00\u6b69\u3092\u8e0f\u307f\u51fa\u3057\u3001\u30a8\u30f3\u30c9\u30c4\u30fc\u30a8\u30f3\u30c9\u306e\u30d7\u30ed\u30bb\u30b9\u3068\u30b7\u30b9\u30c6\u30e0\u306e\u5408\u7406\u5316\u3001\u9023\u643a\u306e\u5f37\u5316\u3001\u305d\u3057\u3066\u81e8\u5e8a\u8a66\u9a13\u5168\u4f53\u306e\u30d1\u30d5\u30a9\u30fc\u30de\u30f3\u30b9\u5411\u4e0a\u3092\u76ee\u6307\u3057\u307e\u3059\u3002\u3053\u308c\u306f\u696d\u754c\u5168\u4f53\u306e\u52d5\u5411\u3092\u53cd\u6620\u3057\u3066\u304a\u308a\u3001³Ô¹Ï±¬ÁÏ 2017 Unified Clinical Operations Survey<\/a><\/strong>\u306e\u56de\u7b54\u8005\u306e\u307b\u307c\u5168\u54e1\uff0899%\uff09\u304c\u3001\u81e8\u5e8a\u8a66\u9a13\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u3092\u7d71\u5408\u5316\u3059\u308b\u5fc5\u8981\u304c\u3042\u308b\u3068\u5831\u544a\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n ³Ô¹Ï±¬ÁÏ\u306e\u30e8\u30fc\u30ed\u30c3\u30d1R&D\u30b9\u30c8\u30e9\u30c6\u30b8\u30fc\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3067\u3042\u308bRik Van Mol\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u6cbb\u9a13\u4f9d\u983c\u8005\u306f\u3001\u30b7\u30b9\u30c6\u30e0\u3068\u30d7\u30ed\u30bb\u30b9\u306e\u7d71\u5408\u5316\u3092\u9032\u3081\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u54c1\u8cea\u3092\u5411\u4e0a\u3055\u305b\u3001\u8a66\u9a13\u5b9f\u65bd\u3092\u52b9\u7387\u5316\u3059\u308b\u3068\u5171\u306b\u3001\u5897\u5927\u3059\u308b\u81e8\u5e8a\u8a66\u9a13\u6570\u3068\u307e\u3059\u307e\u3059\u8907\u96d1\u5316\u3057\u3066\u3044\u308b\u81e8\u5e8a\u8a66\u9a13\u30e9\u30a4\u30d5\u30b5\u30a4\u30af\u30eb\u5168\u4f53\u3092\u7ba1\u7406\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3059\u3002Debiopharm\u793e\u306f\u3001³Ô¹Ï±¬ÁÏ Vault eTMF\u306b\u3088\u308a\u81e8\u5e8a\u8a66\u9a13\u306e\u53ef\u8996\u6027\u3068\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u3092\u5411\u4e0a\u3055\u305b\u3001\u7d71\u5408\u5316\u3055\u308c\u305f\u81e8\u5e8a\u8a66\u9a13\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u3078\u3068\u79fb\u884c\u3067\u304d\u307e\u3059\u3002\u300d<\/p>\n ³Ô¹Ï±¬ÁÏ Vault eTMF\u306f³Ô¹Ï±¬ÁÏ Vault Clinical Suite<\/a><\/strong>\u306e\u4e00\u90e8\u3067\u3059\u3002\u3053\u306e\u30b9\u30a4\u30fc\u30c8\u306f\u3001eTMF\u3001EDC\u3001CTMS\u3001\u304a\u3088\u3073study start-up\u3092\u7d44\u307f\u5408\u308f\u305b\u305f\u696d\u754c\u521d\u306e\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u30b9\u30a4\u30fc\u30c8\u3067\u3001\u81e8\u5e8a\u8a66\u9a13\u30c7\u30fc\u30bf\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u3068\u81e8\u5e8a\u8a66\u9a13\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u3092\u7d71\u5408\u5316\u3057\u307e\u3059\u3002³Ô¹Ï±¬ÁÏ Vault Clinical Suite\u306e\u5229\u7528\u306b\u3088\u308a\u3001\u5404\u81e8\u5e8a\u8a66\u9a13\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u306b\u308f\u305f\u308b\u30b7\u30b9\u30c6\u30e0\u306e\u30b5\u30a4\u30ed\u5316\u3092\u7d44\u7e54\u304c\u3044\u304b\u306b\u3057\u3066\u53d6\u308a\u9664\u3044\u3066\u3044\u308b\u306e\u304b\u3001\u662f\u975eveeva.com\/jp\/Clinical<\/a><\/strong>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n <\/p>\n \u3010³Ô¹Ï±¬ÁÏ Systems\u793e\u306b\u3064\u3044\u3066\u3011 \u3010Forward-looking Statements\u3011<\/strong> 2018\u5e745\u67089\u65e5 ³Ô¹Ï±¬ÁÏ Japan\u682a\u5f0f\u4f1a\u793e ³Ô¹Ï±¬ÁÏ Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 …<\/p>\n","protected":false},"author":131,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322],"tags":[],"class_list":["post-41372","post","type-post","status-publish","format-standard","hentry","category-press-release","blog-product-veeva-rd"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/41372"}],"collection":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=41372"}],"version-history":[{"count":1,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/41372\/revisions"}],"predecessor-version":[{"id":41375,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/41372\/revisions\/41375"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=41372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=41372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=41372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n<\/strong>³Ô¹Ï±¬ÁÏ Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u3084\u305d\u306e\u4ed6\u306e\u898f\u5236\u3092\u53d7\u3051\u308b\u88fd\u9020\u696d\u8005\u5411\u3051\u306b\u3001\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u3067600\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u3092\u64c1\u3057\u3001\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u3092\u30b5\u30dd\u30fc\u30c8\u3057\u3066\u3044\u307e\u3059\u3002³Ô¹Ï±¬ÁÏ\u306f\u3001\u30b5\u30f3\u30d5\u30e9\u30f3\u30b7\u30b9\u30b3\u306e\u30d9\u30a4\u30a8\u30ea\u30a2\u306b\u672c\u793e\u3092\u7f6e\u304d\u3001\u30e8\u30fc\u30ed\u30c3\u30d1\u3001\u30a2\u30b8\u30a2\u3001\u30e9\u30c6\u30f3\u30a2\u30e1\u30ea\u30ab\u306b\u62e0\u70b9\u3092\u5c55\u958b\u3057\u3066\u3044\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001\u516c\u5f0f\u30b5\u30a4\u30c8<\/a><\/strong>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ\u2019s products and services, the results from use of ³Ô¹Ï±¬ÁÏ\u2019s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended January 31, 2018. This is available on the company\u2019s website at www.veeva.com<\/a> under the Investors section and on the SEC\u2019s website at www.sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.<\/p>\n","protected":false},"excerpt":{"rendered":"